ROCHE HOLDING AG

Press Releases Roche Holding AG

Stocks

ROP

CH1499059983

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:33 10/07/2026 BST			5-day change	1st Jan Change
336.60 ^CHF	+0.33%		-1.17%	+2.56%

07-09	Roche's Tuberculosis Test Receives CE Mark	MT
07-08	ABB Robotics Partners with Roche Diagnostics	MT

Press Releases

07-07	Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC	BU
07-02	Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer	BU
06-30	FDA grants Priority Review to Roche's Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)	AQ
06-30	FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)	BU
06-18	FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma	BU
06-11	FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer	BU
06-04	Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection	PR
06-02	FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting	BU
06-01	Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions	BU
05-19	Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer	BU
05-15	FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment	BU
04-30	Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026	BU
04-24	Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign	BU
04-22	Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD	AQ
04-22	Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS	BU
04-21	Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD	BU
04-21	CORRECTING and REPLACING FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus	BU

No results match your criteria

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Roche Holding: An assuring start to the year

Roche Holding: An assuring start to the year

April 23, 2026 at 02:32 pm

The Price of Patience

April 23, 2026 at 10:17 am

The Price of Patience

Google lets you customize your preferred sources.

G Google

Choose MarketScreener

G Google

Choose MarketScreener